Cantargia AB

Cantargia AB maintains a strong liquidity position, with a current ratio of 9.8 and no long-term debt, indicating a robust balance sheet and minimal leverage risk. The company's liquidity_fpt score is high, supported by a free cash flow of 149.8 million SEK and a market cap of 750.3 million SEK, which provides flexibility for R&D and operational needs. Profitability metrics show a return on equity (ROE) of 55.28% and a return on assets (ROA) of 49.54%, both significantly above the industry median for biotechnology firms. These figures suggest efficient use of equity and assets to generate returns. The company's net income of 146.97 million SEK and operating income of 154.1 million SEK further reinforce its strong earnings performance. Geographically, Cantargia's revenue is primarily concentrated in its home market of Sweden, with limited diversification into other regions. The company does not disclose segment-specific revenue breakdowns, but its operations are centered on R&D and clinical trials for oncology treatments. This concentration may expose the company to regulatory and market risks in the Nordic region. Looking ahead, Cantargia is projected to maintain a stable revenue trajectory, with no significant growth or decline expected in the next fiscal year. The company's current price-to-earnings (P/E) ratio of 5.11 is well below the industry median, suggesting it may be undervalued relative to peers. Analysts have assigned a mean price target of 9.17 SEK, with a median of 8.50 SEK, indicating a potential upside of over 200% from the current market price of 3.018 SEK. Risk factors for Cantargia include the inherent volatility of the biotechnology sector, including clinical trial outcomes and regulatory approvals. The company's risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. However, the absence of long-term debt and the presence of a strong cash position mitigate credit risk. The company has not issued any dilutive securities in recent periods, and no dilution pressure is currently expected. Recent events include strong analyst sentiment, with a mean recommendation of 1.50 (favoring "strong buy") and a high price target range of 5.00 to 14.00 SEK. The company has not filed any recent 10-K or 10-Q disclosures that would indicate material changes in its business or financial condition.